Louise Rodino-Klapac - 09 Mar 2026 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
President, R&D and Tech Ops
Signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac
Issuer symbol
SRPT
Transactions as of
09 Mar 2026
Net transactions value
$0
Form type
4
Filing time
11 Mar 2026, 20:04:04 UTC
Previous filing
03 Mar 2026
Next filing
13 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rodino-Klapac Louise President, R&D and Tech Ops 215 FIRST STREET, SUITE 415, CAMBRIDGE /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac 11 Mar 2026 0001836218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability -504 -0.22% $16.95* 227,166 09 Mar 2026 Direct F1
transaction SRPT Common Stock Tax liability -895 -0.39% $16.95* 226,271 09 Mar 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.
F2 Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.